"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 3 | 5 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 7 | 8 |
| 2000 | 6 | 0 | 6 |
| 2001 | 5 | 1 | 6 |
| 2002 | 10 | 3 | 13 |
| 2003 | 2 | 6 | 8 |
| 2004 | 4 | 3 | 7 |
| 2005 | 3 | 4 | 7 |
| 2006 | 6 | 5 | 11 |
| 2007 | 4 | 2 | 6 |
| 2008 | 3 | 2 | 5 |
| 2009 | 8 | 3 | 11 |
| 2010 | 7 | 4 | 11 |
| 2011 | 3 | 3 | 6 |
| 2012 | 3 | 8 | 11 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 4 | 8 | 12 |
| 2016 | 5 | 4 | 9 |
| 2017 | 6 | 3 | 9 |
| 2018 | 3 | 8 | 11 |
| 2019 | 3 | 6 | 9 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 10 | 12 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 9 | 9 |
| 2024 | 1 | 9 | 10 |
| 2025 | 2 | 6 | 8 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response. Vaccine. 2026 Mar 19; 76:128296.
-
Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2. Front Immunol. 2025; 16:1673460.
-
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol. 2025 Nov; 88(5):430-434.
-
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
-
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone? or Flublok?) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45?years of age. Vaccine. 2025 04 30; 54:126991.
-
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Gu?rin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. Eur Urol Focus. 2025 May; 11(3):448-455.
-
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
-
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 02 15; 47:126689.
-
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans. Nat Immunol. 2025 Jan; 26(1):116-130.
-
Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 12; 18(12):e0012788.